Flightpath Biosciences
Mr. Tindall has extensive entrepreneurial management experience as a CEO/Executive/Co-Founder of healthcare companies in the rare disease, oncology, pain, cardiovascular and genomics spaces with Fabric Genomics, Kodikaz, Wheatsheaf Group, IQVIA, Digitas Health, Genzyme Corporation, Celera Genomics, Eli Lilly & Company and Sarentis Therapeutics.
Flightpath Biosciences
Flightpath Biosciences uses advanced drug discovery tools to identify optimal therapeutic candidates and cutting-edge drug delivery technology to vastly improve drug targeting and safety, reduce negative impacts on the microbiome, speed the time-to-market and eliminate non-target antibiotic resistance risks.